ZA200608986B - Process for the preparation of Valsartan and precursors thereof - Google Patents

Process for the preparation of Valsartan and precursors thereof Download PDF

Info

Publication number
ZA200608986B
ZA200608986B ZA200608986A ZA200608986A ZA200608986B ZA 200608986 B ZA200608986 B ZA 200608986B ZA 200608986 A ZA200608986 A ZA 200608986A ZA 200608986 A ZA200608986 A ZA 200608986A ZA 200608986 B ZA200608986 B ZA 200608986B
Authority
ZA
South Africa
Prior art keywords
formula
compound
process according
group
temperature
Prior art date
Application number
ZA200608986A
Other languages
English (en)
Inventor
Bessa Bellmunt Jordi
Huguet Clotet Joan
Perez Andres Juan Antonio
Dalmases Barjoan Pere
Original Assignee
Inke Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inke Sa filed Critical Inke Sa
Publication of ZA200608986B publication Critical patent/ZA200608986B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA200608986A 2004-04-20 2005-04-18 Process for the preparation of Valsartan and precursors thereof ZA200608986B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200400949A ES2251292B1 (es) 2004-04-20 2004-04-20 Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.

Publications (1)

Publication Number Publication Date
ZA200608986B true ZA200608986B (en) 2008-02-27

Family

ID=34966329

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608986A ZA200608986B (en) 2004-04-20 2005-04-18 Process for the preparation of Valsartan and precursors thereof

Country Status (13)

Country Link
US (1) US7728021B2 (https=)
EP (1) EP1747190B1 (https=)
JP (1) JP2007533727A (https=)
KR (1) KR20060135959A (https=)
AT (1) ATE401300T1 (https=)
DE (1) DE602005008224D1 (https=)
ES (2) ES2251292B1 (https=)
PL (1) PL1747190T3 (https=)
PT (1) PT1747190E (https=)
SI (1) SI1747190T1 (https=)
TW (1) TWI283576B (https=)
WO (1) WO2005102987A1 (https=)
ZA (1) ZA200608986B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618097A1 (en) 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
EP1838681A2 (en) * 2004-12-22 2007-10-03 Enantia, S.L. Intermediate compounds for the preparation of an angiotensin ii receptor and process for the preparation of valsartan
ES2259909B1 (es) 2005-02-28 2007-06-16 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis.
WO2007005967A2 (en) * 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
ITMI20051989A1 (it) * 2005-10-20 2007-04-21 Dipharma Spa Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
ES2300175B1 (es) * 2006-02-14 2009-06-08 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2008007391A2 (en) * 2006-07-10 2008-01-17 Manne Satyanarayana Reddy An improved process for the preparation of valsartan
EP1849777B1 (en) * 2007-06-07 2008-10-29 Inke, S.A. Process for obtaining a valsartan salt useful for obtaining valsartan
US8492577B2 (en) 2008-04-07 2013-07-23 Hetero Research Foundation Process for preparation of valsartan intermediate
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
CN102702118B (zh) * 2012-06-11 2014-04-16 吉林三善恩科技开发有限公司 一种缬沙坦有机药物共晶及其制备方法
CN103804313B (zh) * 2014-01-27 2015-12-09 云南现代民族药工程技术研究中心 一种简洁的低成本高效率制备缬沙坦的方法
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
DE4319040A1 (de) 1992-10-23 1994-04-28 Bayer Ag Alkoxymethylsubstituierte Pyridonbiphenyle
DE4319041A1 (de) * 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
DE4313747A1 (de) * 1993-04-27 1994-11-03 Bayer Ag Verfahren zur Herstellung von substituierten Biphenyltetrazolen
DE4320432A1 (de) * 1993-06-21 1994-12-22 Bayer Ag Substituierte Mono- und Bipyridylmethylderivate
DE4407488A1 (de) 1994-03-07 1995-09-14 Bayer Ag Verwendung von Biphenyl- und Pyridylmethylpyridonen
DE69507887T2 (de) 1994-09-20 1999-06-17 Wakunaga Seiyaku K.K., Osaka Verfahren zur herstellung von n-biphenylmethylthiadiazolin derivaten oder deren salzen sowie dafür benötigte zwischen verbindungen
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
ATE277913T1 (de) * 2001-01-19 2004-10-15 Pharmacopeia Inc Bisarylderivate mit fsh rezeptor modulierender aktivität
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SI1747190T1 (sl) 2008-12-31
WO2005102987A1 (en) 2005-11-03
KR20060135959A (ko) 2006-12-29
ES2251292A1 (es) 2006-04-16
PT1747190E (pt) 2008-09-29
US20090221836A1 (en) 2009-09-03
EP1747190A1 (en) 2007-01-31
TWI283576B (en) 2007-07-11
PL1747190T3 (pl) 2009-01-30
DE602005008224D1 (de) 2008-08-28
ES2251292B1 (es) 2007-07-01
EP1747190B1 (en) 2008-07-16
ES2309741T3 (es) 2008-12-16
US7728021B2 (en) 2010-06-01
JP2007533727A (ja) 2007-11-22
TW200539873A (en) 2005-12-16
ATE401300T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
ZA200608986B (en) Process for the preparation of Valsartan and precursors thereof
JP5202635B2 (ja) インテグラーゼ阻害剤の調製のためのプロセスおよび中間体
CN105263913B (zh) 硫代1,2,4‑三唑衍生物及其制备方法
JPH01117876A (ja) 抗高血圧化合物のためのテトラゾール中間体
EP4010318A1 (en) Processes for the preparation of roxadustat and intermediates thereof
JP2008088172A (ja) フェニルテトラゾール化合物の製法
SK286740B6 (sk) Spôsob syntézy draselnej soli losartanu
EP1853591B1 (en) Method for obtaining a pharmaceutically active compound (irbesartan) and its synthesis intermediate
US5977372A (en) Chloro or bromo[2-[2-(tert-butyl)-2H-tetrazol-5-yl]phenyl]zinc intermediates
JP2007112800A (ja) アンジオテンシンｉｉ拮抗化合物の製造方法
JP4433365B2 (ja) ４−（２−メチル−１−イミダゾリル）−２，２−ジフェニルブタンアミドの製造方法
EP2170837B1 (en) Process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl)-phenyl)-2-methylpropionic acid
EP1937654B1 (en) Process for obtaining valine derivatives useful for obtaining a pharmaceutically active compound
US6326498B1 (en) Process for the synthesis of 5-(2-flurophenyl)-1H-tetrazole
JP5087059B2 (ja) ４−（２−メチル−１−イミダゾリル）−２，２−ジフェニルブタンアミドの製造方法
JP4316686B2 (ja) シクロヘプトイミダゾール誘導体
EP1891053A1 (en) Method for obtaining benzimidazole derivatives and intermediates thereof
SE505562C2 (sv) Karboximetylidencykloheptimidazolderivat, förfarande för deras framställning och terapeutiska medel innehållande dessa föreningar
JPS5916879A (ja) Ｎ−置換イミダゾ−ル類の製造法
EP0345998A1 (en) Process and intermediates for beta-lactam antibiotics
JPH09176129A (ja) ２−アルキル−４−クロロ−５−ヒドロキシメチルイミダゾール誘導体の製造法
JPH0632782A (ja) ピラゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤